Agenus Inc (NASDAQ:AGEN)

2.55
Data as of Apr 17
 +0.14 / +5.81%
Today’s Change
2.27
Today|||52-Week Range
5.40
-3.41%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$176.6M

Company Description

Agenus, Inc. is a biotechnology company, which is focused on the development and commercialization of technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Its core technology portfolio consists of Saponin platform and Heat Shock Protein platform. The company within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by its licensees in numerous vaccines under development in clinical trials, some as advanced as phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus and tuberculosis. Agenus within its HSP Platform is developing its recombinant series and prophage series vaccines. The company's HerpV, a therapeutic vaccine candidate from the recombinant series, which contains QS-21 Stimulon, has been tested in a phase 1 clinical trial for the treatment of genital herpes. Agenus was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

Contact Information

Agenus, Inc.
3 Forbes Road
Lexington Massachusetts 02421-7305
P:(781) 674-4400
Investor Relations:
(781) 674-4538

Employees

Shareholders

Individual stakeholders4.66%
Mutual fund holders4.14%
Other institutional30.16%

Top Executives

Garo H. ArmenChairman & Chief Executive Officer
Christine M. KlaskinVP, Chief Financial & Accounting Officer
Kerry A. WentworthVice President-Clinical, Regulatory & Quality
Robert B. SteinChief Scientific Officer
John CerioVice President-Human Resources & Administration

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.